Description: Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com
Home Page: www.plandaibiotech.com
17 Hanover Square
London,
W1S 1BN
United Kingdom
Phone:
44 91 7900 9829
Officers
| Name | Title |
|---|---|
| Mr. Roger Baylis-Duffield | Co-Founder, Chairman and Chief Exec. Officer |
| Mr. Callum Baylis-Duffield | Pres, Chief Operating Officer and Director |
| Mr. Ezra Jones | VP of Sales and Marketing |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 1.045 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 250 |